Open Actively Recruiting

Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

About

Brief Summary

Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.

Study Type
observational_patient_registry

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

  • Males and females aged 18 years and older
  • Patients with known Alpha-1 Anti-trypsin deficiency (PiZZ)
  • Be an existing member of the Alpha-1 Foundation Clinical Cohort (Alpha-1 Foundation Research Registry)
  • Willingness to perform study procedures of Chest CT, blood biomarker determination, sputum collection, questionnaire completion, and lung function testing.

Exclusion Criteria:

  • AATD non-PiZZ status, including carriers
  • Pregnancy at the time of the screening visit

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
22-000634
Category
Pulmonary Disease
Contact
Donghyun Jung
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05297812
For detailed technical eligibility, visit ClinicalTrials.gov.